ASGE Annual GI Advanced Practice Provider Course (Virtual) (Day One) | March 2026-Radiology Studies Case1-Pancreatic Cystic Lesions and IPMNs

Pdf Summary

This presentation reviews pancreatic cystic lesions, with emphasis on mucinous cysts and intraductal papillary mucinous neoplasms (IPMN), focusing on diagnosis, risk stratification, and management. Pancreatic cysts are common incidental findings, with global prevalence around 13–18% and increasing markedly after age 50. Key clinical goals are distinguishing mucinous from nonmucinous cysts, estimating malignant potential, and deciding between surgery, surveillance, or no follow-up.<br /><br />Cyst types include mucinous lesions (IPMN, mucinous cystic neoplasm [MCN]), nonmucinous neoplasms (serous cystadenoma [SCA], solid pseudopapillary neoplasm, cystic pancreatic neuroendocrine tumor), and inflammatory pseudocysts. Evaluation relies on high-quality cross-sectional imaging (CT/MRI/MRCP) assessing morphology and pancreatic duct (PD) communication, plus endoscopic ultrasound (EUS) with fine-needle aspiration (FNA) when indicated. EUS-FNA has low but real risks (overall morbidity ~2.7%; pancreatitis ~0.9%).<br /><br />Risk stratification uses “high-risk stigmata” (e.g., obstructive jaundice with head lesion, enhancing mural nodule ≥5 mm, main pancreatic duct [MPD] ≥10 mm) and “worrisome features” (e.g., cyst ≥3 cm, mural nodule <5 mm, thick/enhancing walls, MPD 5–9 mm, abrupt duct caliber change with atrophy, lymphadenopathy, elevated CA 19-9, rapid growth). Cyst fluid analysis helps classification: CEA ≥192 ng/mL suggests mucinous cysts (not cancer-specific); high amylase suggests PD communication (IPMN/pseudocyst); low glucose supports mucinous etiology. Serum CA 19-9 trends may aid detecting malignant transformation but have limitations.<br /><br />Cases highlight: main-duct IPMN (high malignancy risk ~70%) generally warrants surgery (e.g., Whipple) and post-op surveillance; branch-duct IPMN has lower malignancy risk (~15%) and is often monitored if no high-risk features; MCN (typically women, body/tail, no duct communication, high CEA/low amylase) is usually resected; SCA is benign and typically observed unless large/symptomatic. Guidelines (ACG/IAP/AGA/ACR) vary, especially on when to stop surveillance (5–10 years vs lifelong).

Asset Subtitle

Sarah Enslin, PA-C, and Vivek Kaul, MD, FASGE

Keywords

pancreatic cystic lesions

mucinous cysts

intraductal papillary mucinous neoplasm (IPMN)

mucinous cystic neoplasm (MCN)

serous cystadenoma (SCA)

endoscopic ultrasound with FNA (EUS-FNA)

high-risk stigmata and worrisome features

main pancreatic duct dilation

cyst fluid CEA amylase glucose

surveillance and management guidelines (ACG IAP AGA ACR)